Karen Sielaff

445 citations
11 papers · 333 indexed · h-index 9

Karen Sielaff

11 papers receiving 314 citations

Peers

Karen Sielaff
Comparison fields: 5 of 68
  • Immunology 116
  • Oncology 112
  • Genetics 32
  • Pathology and Forensic Medicine 54
  • Biochemistry 19
Replace Y Basaki with:
Y Basaki Japan
H.-J. Thiesen Germany
Rupert Engelhardt Germany
Mei Liu China
Anna Wolska Poland
Reba M. Knox United States
T. C. Alford United States
Panayi Gs United Kingdom
Yong Shao China
Eun‐Ji Choi South Korea
Karen Sielaff relative to Y Basaki Japan Y Basaki's profile →
Citations per field
00.5×3.8×
Y Basaki · 1×
Citations per year

Countries citing papers authored by Karen Sielaff

Since Specialization
Citations

This map shows the geographic impact of Karen Sielaff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Sielaff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Sielaff more than expected).

Fields of papers citing papers by Karen Sielaff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Sielaff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Sielaff. The network helps show where Karen Sielaff may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Karen Sielaff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Karen Sielaff Line = papers co-authored together Karen Sielaff links everyone, so they are left out of the graph.

All Works

11 of 11 papers shown
#Work
1 201071
2
In vivo priming effects of interferon-beta ser on NK activity of peripheral blood mononuclear cells in cancer patients.
19955
3 199215
4 198911
5 198963
6
Phase I trial of human lymphoblastoid interferon with whole body hyperthermia in advanced cancer.
198924
7
A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
19891
8 198825
9 198634
10 198632
11
Phase I evaluation of a synthetic mutant of beta-interferon.
198552

About Karen Sielaff

Karen Sielaff is a scholar working on Immunology, Oncology and Critical Care and Intensive Care Medicine, having authored 11 papers that have together received 333 indexed citations. Recurring topics across this work include Cytokine Signaling Pathways and Interactions (5 papers), interferon and immune responses (4 papers), Immune Response and Inflammation (3 papers), Lymphoma Diagnosis and Treatment (3 papers), Immune Cell Function and Interaction (2 papers), NF-κB Signaling Pathways (2 papers), Cell death mechanisms and regulation (1 paper) and Respiratory viral infections research (1 paper). The work is most often cited by research in Immunology (116 citations), Oncology (112 citations) and Genetics (32 citations). Karen Sielaff has collaborated with scholars based in United States, Switzerland and Japan. Frequent co-authors include Ernest C. Borden, Michael Hawkins, L. Andrew Ball, James A. Merritt, Anne P. Teitelbaum, R. R. Brown, Patricia L. Witt, R V Smalley, Daniel A. Goldstein and S. P. Datta. Their work appears in journals such as JNCI Journal of the National Cancer Institute, Journal of neurosurgery and Cancer Prevention Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026